BrainsWay (NASDAQ:BWAY) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
Volatility and Risk
BrainsWay has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.
This is a summary of recent ratings for BrainsWay and DarioHealth, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BrainsWay presently has a consensus target price of $14.00, suggesting a potential upside of 79.95%. DarioHealth has a consensus target price of $26.35, suggesting a potential upside of 97.82%. Given DarioHealth’s higher possible upside, analysts plainly believe DarioHealth is more favorable than BrainsWay.
Insider & Institutional Ownership
46.5% of BrainsWay shares are held by institutional investors. Comparatively, 45.9% of DarioHealth shares are held by institutional investors. 14.1% of DarioHealth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares BrainsWay and DarioHealth’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BrainsWay||$22.06 million||5.80||-$5.39 million||($0.24)||-32.42|
|DarioHealth||$7.58 million||29.01||-$29.44 million||($4.01)||-3.32|
BrainsWay has higher revenue and earnings than DarioHealth. BrainsWay is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.
This table compares BrainsWay and DarioHealth’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
BrainsWay beats DarioHealth on 8 of the 14 factors compared between the two stocks.
Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.
DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.